Malignant Pleural Mesothelioma market projecting a CAGR of 7.6% during the forecast period, 2020-2026

Malignant Pleural Mesothelioma market

According to BlueWeave Consulting, the global Malignant Pleural Mesothelioma market anticipated to grow by Significant CAGR of 7.6% during the forecast period 2020-2026.The global market for malignant pleural mesothelioma is expected to receive a favorable boost from increased healthcare expenditure in many parts of the world, combined with the availability of better treatment prognosis for malignant pleural mesothelioma.

Malignant pleural mesothelioma is a rare and aggressive cancer that develops in a thin tissue layer called pleura around the lungs. Microscopic inhalation of asbestos fibers causes malignant pleural mesothelioma. According to the NIH, once the individual inhales asbestos particles, the human body fails to remove is about 20 per million inhabitants, and it is -globally. Overall, there’s also increased acceptance of combination therapies on the global malignant pleural mesothelioma sector.

Report Sample Pages At :

Asbestos-exposed individuals are at increased risk of developing malignant pleural mesothelioma. Within contaminated areas, as opposed to non-polluted areas, the risk of malignant pleural mesothelioma is increased by 2 to 10 fold. People who work in mines and are heavily exposed to asbestos are usually at a higher risk of developing malignant pleural mesothelioma. About 2-18 percent of miners and those working in plants containing asbestos are diagnosed with malignant pleural mesothelioma. People who are genuinely interested in the use of asbestos as one of the raw materials are not even spared. It is disturbing to note that people who live near these factories are put at risk of contracting the disease.

Pemetrexed and cisplatin are the standard first-line treatment of pleural mesothelioma with malignancy. It is the most effective chemotherapy treatment. In a recent study to test cisplatin and Pemetrexed called Mesothelioma Avastin Cisplatin Pemetrexed Trial (MAPS), the addition of bevacizumab in patients with minimal side effects of malignant pleural mesothelioma showed significantly improved survival rates. Focus on getting approvals for effective combination therapy. It is believed that exposure to asbestos leads to malignant pleural mesothelioma, and despite the limitations on the global use of asbestos, mesothelioma cases are expected to decline in the forthcoming years.

Nonetheless, those findings are not confirmed by the number of malignant pleural mesothelioma cases. It was observed that there is a growing trend of cases of malignant mesothelioma in men. This specific aspect drives Pemetrexed revenue growth and the combination segment.


North America is the market leader in malignant pleural mesothelioma led by Europe due to higher incidence and prevalence rates, an increase in the geriatric population, and increased demand for advanced therapies. The Asia Pacific is an emerging market for malignant pleural mesothelioma due to healthcare infrastructure development, patient awareness, and increased government spending in the healthcare sector. Low patient awareness, lack of proper treatment, and high therapy costs are factors that narrow the demand for malignant pleural mesothelioma in Middle East & Africa.

Malignant Pleural Mesothelioma market is fragmented owing to the presence of number of large-sized companies that hold the majority share of AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd, Corden Pharma International GmbH, Concordia International Corp and Other Prominent Players.

About Us

BlueWeave Consulting is a one-stop solution for market intelligence regarding various products and services online & offline. We offer worldwide market research reports by analyzing both qualitative and quantitative data to boost up the performance of your business solution. BWC has built its reputation from the scratches by delivering quality performance and nourishing the long-lasting relationships with its clients.


Blueweave consulting
Toll-free: +1-866-658-6826
International: +1-425-320-4776
Email: [email protected]



Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button